ellipticine has been researched along with nalidixic acid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Sumner, AT | 1 |
| DeMarini, DM; Lawrence, BK | 1 |
| Jo, K; Topal, MD | 1 |
5 other study(ies) available for ellipticine and nalidixic acid
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis.
Topics: Amsacrine; Camptothecin; Chromosome Aberrations; Chromosomes, Human; Daunorubicin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Ellipticines; Ethidium; Etoposide; Humans; In Vitro Techniques; Lymphocytes; Mitosis; Mitoxantrone; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1992 |
Prophage induction by DNA topoisomerase II poisons and reactive-oxygen species: role of DNA breaks.
Topics: Amsacrine; Azides; Bacteriophage lambda; Dactinomycin; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Ellipticines; Escherichia coli; Free Radicals; Hydrogen Peroxide; Lysogeny; Nalidixic Acid; Novobiocin; Oxolinic Acid; Oxygen; Paraquat; Sodium Azide; SOS Response, Genetics; Teniposide; Topoisomerase II Inhibitors; Virus Replication | 1992 |
Changing a leucine to a lysine residue makes NaeI endonuclease hypersensitive to DNA intercalative drugs.
Topics: Amsacrine; Antineoplastic Agents; Binding Sites; Daunorubicin; Deoxyribonuclease EcoRI; Deoxyribonucleases, Type II Site-Specific; DNA Nucleotidyltransferases; DNA Topoisomerases, Type I; Ellipticines; Enzyme Inhibitors; Integrases; Intercalating Agents; Kinetics; Lysine; Nalidixic Acid; Novobiocin; Oxolinic Acid; Point Mutation; Recombinant Proteins; Recombinases; Topoisomerase I Inhibitors | 1996 |